- Trial phase
- Approved
- Time to market
- Already on the market since August 2021 (US) for late-onset Pompe disease. Label expansion to infantile-onset Pompe could come in 2027 pending FDA submission and review.
- Why 4/10
- Nexviazyme is already FDA-approved (2021) and generating ~€790M in annual sales. The next hard catalyst is the H2 2026 FDA submission for infantile-onset Pompe label expansion following positive Phase 3 Baby-COMET results (June 30, 2026). No PDUFA date is set yet. As a part of a €43.6B-revenue diversified pharma giant, even a label-expansion approval would drive a modest single-digit % move in SNY shares at most, not a binary event.
The Baby-COMET Phase 3 topline readout (June 30, 2026) was a positive milestone already priced in. Watch for the formal FDA submission in H2 2026 and the eventual PDUFA decision, likely a 2027 event, which could add ~€100-200M in peak sales from the infantile-onset population. The bigger competitive overhang is BioMarin's newly acquired Pombiliti+Opfolda combo, which Danish regulators found equally effective and which may pressure Sanofi's Pompe franchise pricing.
Price Chart
Executive Summary
Nexviazyme (avalglucosidase alfa) is Sanofi's next-generation enzyme replacement therapy for Pompe disease, a rare inherited muscle disorder. Approved by the FDA in August 2021 for late-onset Pompe, it generated ~€790M in 2025 sales (Sanofi's total revenue: €43.6B). On June 30, 2026, Sanofi announced positive Phase 3 Baby-COMET results in infantile-onset Pompe, meeting all endpoints, and plans to file for label expansion in H2 2026. The drug faces growing competition from BioMarin's Pombiliti+Opfolda combo (acquired via $4.8B Amicus deal, closed April 2026) and will cannibalize Sanofi's own older ERT Myozyme/Lumizyme. For a diversified pharma giant, Nexviazyme is a steady rare-disease growth asset but not a stock-moving binary event.
How It Works
Nexviazyme is an enzyme replacement therapy (ERT) for Pompe disease, a rare genetic disorder where the body can't break down a complex sugar called glycogen. Pompe patients lack a working version of an enzyme called GAA. Nexviazyme is an infused version of that enzyme, designed with an enhanced sugar tag (bis-M6P) that helps it get into muscle cells more efficiently than older ERTs, clearing glycogen buildup and slowing muscle damage.
Trial Status
FDA-approved since August 2021 for late-onset Pompe disease (LOPD) based on Phase 3 COMET and Phase 2 mini-COMET studies. On June 30, 2026, Sanofi announced positive Phase 3 Baby-COMET results (NCT04910776) in infantile-onset Pompe disease (IOPD), meeting all primary and secondary endpoints. Sanofi plans to file for FDA label expansion in H2 2026.
The Two-Sided Case
Upcoming Catalysts
- July 8, 2026: Full Baby-COMET Phase 3 data presentation at the 19th International Congress on Neuromuscular Diseases (Florence, Italy).
- H2 2026: FDA submission for infantile-onset Pompe disease label expansion.
- July 30, 2026: Sanofi Q2 2026 earnings, Nexviazyme quarterly sales and franchise update.
- 2027 (estimated): PDUFA decision on infantile-onset Pompe label expansion.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report